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Abstract
Background: The European Medicines Agency (EMA) requires vaccine manufacturers to conduct enhanced real-time surveillance
of seasonal influenza vaccination. The EMA has specified a list of adverse events of interest to be monitored. The EMA sets out
3 different ways to conduct such surveillance: (1) active surveillance, (2) enhanced passive surveillance, or (3) electronic health
record data mining (EHR-DM). English general practice (GP) is a suitable setting to implement enhanced passive surveillance
and EHR-DM.
Objective: This study aimed to test the feasibility of conducting enhanced passive surveillance in GP using the yellow card
scheme (adverse events of interest reporting cards) to determine if it has any advantages over EHR-DM alone.
Methods: A total of 9 GPs in England participated, of which 3 tested the feasibility of enhanced passive surveillance and the
other 6 EHR-DM alone. The 3 that tested EPS provided patients with yellow (adverse events) cards for patients to report any
adverse events. Data were extracted from all 9 GPs’ EHRs between weeks 35 and 49 (08/24/2015 to 12/06/2015), the main period
of influenza vaccination. We conducted weekly analysis and end-of-study analyses.
Results: Our GPs were largely distributed across England with a registered population of 81,040. In the week 49 report,
15,863/81,040 people (19.57% of the registered practice population) were vaccinated. In the EPS practices, staff managed to
hand out the cards to 61.25% (4150/6776) of the vaccinees, and of these cards, 1.98% (82/4150) were returned to the GP offices.
Adverse events of interests were reported by 113 /7223 people (1.56%) in the enhanced passive surveillance practices, compared
with 322/8640 people (3.73%) in the EHR-DM practices.
Conclusions: Overall, we demonstrated that GPs EHR-DM was an appropriate method of enhanced surveillance. However, the
use of yellow cards, in enhanced passive surveillance practices, did not enhance the collection of adverse events of interests as
demonstrated in this study. Their return rate was poor, data entry from them was not straightforward, and there were issues with
data reconciliation. We concluded that customized cards prespecifying the EMA’s adverse events of interests, combined with
EHR-DM, were needed to maximize data collection.
International Registered Report Identifier (IRRID): RR2-10.1136/bmjopen-2016-015469
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Introduction
Background
The European Medicines Agency (EMA) released interim
guidance on enhanced safety surveillance for seasonal influenza
vaccines in August 2014 [1]. All Marketing Authorization
Holders (MAHs) commercializing influenza vaccines in Europe
must follow this guidance which sets out new standards for
safety surveillance. Its goal is to rapidly detect, in near real-time
early in the season, any significant increase in the frequency or
severity of a defined list of adverse events of interest (AEIs).
These AEIs can be local, systemic, or allergic reactions,
indicating a potential or more serious risk.
For this request, the EMA defines 3 types of surveillance: (1)
active surveillance, using existing methods of postauthorization
surveillance; (2) enhanced passive surveillance (EPS), estimating
vaccine usage rapidly and taking additional steps to facilitate
passive adverse drug reactions (ADR) reporting of incidence
of AEIs; and (3) electronic health record data mining
(EHR-DM).
English general practice (GP) is a suitable setting to implement
EPS and EHR-DM, as it has a registration-based list system
with linked medical records, it has been highly computerized
since 2004, and data extracted from these systems are widely
used in research [2,3]. Furthermore, GPs are largely independent
professional partnerships and make their own decision about
which brand of influenza vaccine to purchase before the start
of each influenza season [4]. Practices administer influenza
vaccines to recommended groups, starting in September of each
year [5].
Objectives
In 2015-16, one of the major suppliers of influenza vaccines to
UK health care was GSK (GlaxoSmithKline). Collaborating
with the University of Surrey, GSK took the opportunity of the
UK computerized infrastructure to implement EPS and
EHR-DM with the aim to test the feasibility of using EPS and
EHR-DM within GP to identify AEIs in subjects vaccinated
with GSK’s and other influenza vaccine brands. An additional
aim was to ascertain if using EPS in GP has any advantages
over EHR-DM alone. The key components of this surveillance
were as follows: (1) to provide a weekly estimation of vaccine
coverage, by age, risk group, and vaccine brand; and (2) to
estimate weekly AEI reporting rates among subjects vaccinated
against seasonal influenza, by age, comorbidity, and brand from
the GPs using the EHR-DM method, and those using the EPS
system.
Methods
Setting
Following the request of EMA stating that MAHs must conduct
enhanced seasonal influenza vaccines safety surveillance, GSK,
together with the University of Surrey, launched a pilot safety
surveillance study for GSK’s seasonal influenza vaccines. The
University of Surrey has developed methods to extract timely
surveillance data from GP. This system was developed to
support the Royal College of General Practitioners (RCGP)
Research and Surveillance Centre (RSC) weekly surveillance
reports [6] and is capable of being adapted to support the
EMA-specified surveillance (ClinicalTrials.gov number:
NCT02567721).
We recruited 9 GPs spread across England, from varying types
of locality (North and South, and urban and rural) and using
different EHR systems (Egton Medical Information Systems)
and The Phoenix Partnership). We compared the demographic
characteristics—age, gender, ethnicity, and deprivation
scores—using the Index of Multiple Deprivation, on the basis
of each patient’s Lower Super Output Area (a small local
geographical location [7,8]) of the registered population, with
the national average data obtained from the Office for National
Statistics [9].
Design
This feasibility study period ran from International Organization
for Standardization (ISO) week 35 to week 49 of 2015
(08/24/2015 to 12/06/2015).
As this was a feasibility study, there was no attempt to determine
a priori the size of the study on the basis of power calculation.
However, considering the average GP size of 7034 in England
and Wales, it was expected that 9 GPs would provide a study
population of 63,300. Ultimately, the population registered in
the recruited practices was larger (N=81,040).
GPs were recruited in summer 2015; some months after they
had selected their brand of vaccine for the coming influenza
season. Out of the 9 practices recruited, 3 joined the EPS group
and 6 joined the EHR-DM group. As this was a feasibility study,
there was no attempt to randomize the practices into groups
according to the type and brand of seasonal influenza vaccine
used by the practices. Each group (EPS vs EHR-DM) was based
on practices’ willingness to participate in the study.
The EPS group involved every patient who was vaccinated and
received a yellow card; on the basis of the standard ADR cards
used by the Medicines & Healthcare Products Regulatory
Agency (MHRA) [10]. The patients were asked to complete a
yellow card if they experienced an AEI in the 14-day
postvaccination window; they were invited to return the card
to their registered practice. The reported information was coded
into the patient’s EHR by their GP and extracted weekly:
• EHR data mining: The EHR-DM group (n=6) had routine
clinical data extracted from their EHR, pseudonymized and
automatically sent to a secure sever on a weekly basis. In
case of data extraction failure, a local data extraction was
conducted using a Department of Health data extraction
tool (MIQUEST—Morbidity Information Query and Export
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Syntax [11,12]). All practices in the EHR-DM group used
a non-GSK influenza vaccine.
• Enhanced passive surveillance: The EPS group of practices
(n=3) had their routine clinical data extracted from their
EHR in the same way as the EHR-DM group. In addition,
these practices also distributed a yellow card to patients
receiving the seasonal influenza vaccine. Patients were
asked to return the card to their own practice within 14
days. The information in the returned cards was then coded
by practice staff into each patient’s EHR and then extracted
in the same manner as the EHR-DM group. In this group,
2 practices used GSK influenza vaccine and 1 practice
non-GSK vaccines.
All practices were given induction training and a preferred code
list for the specific AEIs identified by EMA to facilitate
standardized data coding. We created this list using an
ontological approach [13,14]. We grouped these conditions into
body system categories: respiratory, gastrointestinal, fever,
sensitivity and anaphylaxis, rash, general symptoms,
neurological, musculoskeletal, and local reactions (Multimedia
Appendix 1). We provided GPs a full code list and a screen-side
prompt list.
We requested that, when a patient presented with one of these
conditions, they should use the recommended code (as per the
instruction sheet). We advised GPs that GPs should code the
conditions they felt a patient was reporting accurately. We
stressed that the overarching purpose was not to purposively
make any causal link between vaccination and a given condition,
particularly for common conditions, such as cold and headache.
However, they were reminded that they should report, in parallel
to this study, any serious or important events on the basis of
their professional judgment through the standard MHRA
reporting system as per local regulation.
Study Measures
The primary outcome measure was to report AEI frequencies
among influenza-vaccinated subjects and observe any
discrepancies in these frequencies in the EPS versus EHR-DM
group and GSK versus non-GSK vaccines. To identify event
date, we used the event date for the actual episode, not the
recorded date.
• Estimation of vaccine uptake rates by age-band, risk group,
and vaccine brand: We classified patients as vaccinated
when a prescription or administration code for an influenza
vaccine was recorded in the patient’s EHR. Whichever had
the earliest date was taken as the vaccine administration
date; prescription issue dates often lag behind the
administration dates.
• Estimation of AEI rates by age, risk group, vaccination
status, and vaccine brand: We included presentations up to
14 days, notwithstanding the EMA recommendations being
for 7 days, to allow for any lag between experiencing an
AEI and obtaining an appointment to see a GP or to return
the yellow card. Both EHR and yellow card data were used
to estimate AEIs in the EPS practices. We predicted that
the yellow cards would increase AEI reporting; therefore,
EPS practices should have a larger percentage of AEIs
recorded.
• To observe the reporting trend from a broader pool of GPs,
we also extracted the AEIs from the RCGP RSC Network:
We focused on records of vaccinated subjects only, using
data for the same weeks (35-49) in 2015. We did not include
any events before vaccination for the 9 study practices or
the RCGP RSC network. Analysis was concentrated on
AEIs at any time after vaccination (not just in the 14-day
window after vaccination).
Throughout the study, we produced weekly reports of AEIs. At
the end of the study, we produced an end-of-season report. The
end-of-season report enabled us to identify whether the approach
was appropriate to adequately capture the vaccination uptake,
to enhance the collection of AEs, easily transcribe the events
reported from the yellow cards to the electronic system, more
comprehensively capture the AEIs experienced, and extract
them on an ongoing basis in a near real-time manner.
• Weekly reports: We produced weekly reports of the
incidence of AEIs in influenza-vaccinated patients. We also
reported cumulative vaccination rates. These weekly reports
were intended to be produced the week following data
recording. These reports provided practices feedback about
the rate of AEIs recorded in their practice to encourage data
recording. We reported the cumulative data adding the
information as the data collection was progressing with
patients registered until week 49 with the objective to assess
the data in a near real-time manner. We included all patients
with a valid registration (defined as fully registered with a
valid registration) on the Friday of the week, before data
extraction took place.
• End of study period analysis: We conducted an analysis at
the end of the study period between weeks 35 and 49. We
included patients registered with the pilot practices
throughout the whole observation period with medical
records valid 12 months before the start of the study; this
objective being to ensure further that we had sufficient
medical history about any long-term condition that might
affect their priority for influenza vaccination.
Our established data extraction method means that only coded
data (Read code version 2 and CTV3) [15] were used to collect
the relevant information. Free text was not extracted as it might
include patient identifiable information. We excluded people
with a code that indicated that they opted out of sharing data;
estimated at around 1.25% of the registered population [16].
Data were pseudonymized as close to source as possible and
encrypted.
Analyses
For all AEIs, we report the rate and the 95% CI, using the critical
binomial function in Microsoft Excel [17].
Results
Setting
Our practices were largely distributed across England, with
most in the Midlands and East National Health Service (NHS)
Region (NHS Regions: North, n=3; Midlands and East, n=5;
and South, n=1). Practices were mainly from urban areas (rural,
n=3; and urban, n=6). In the week 49 weekly report (data
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extracted in a near real-time manner), the overall population
registered in the 9 GP practices was 81,040. The end-of-study
cohort population was 71,407 (owing to restriction of longer
registration as described earlier).
In the week 49 data extraction, the practice populations had a
female to male ratio of 49.76% (40, 323/81,040) to 50.24%
(40,717/81,040. The proportion of people aged 20 to 24 years
and over 50 years was above the national average (Figure 1).
The study population had a higher proportion of people of white
ethnicity recorded 92.57% (38,154/41,218 compared with
85.42% nationally; (45,281,142/53,012,456). The study
population was less deprived than the national average, with
almost three-fourths 72.20% (56,545/78,322) of the population
in the least deprived half (Multimedia Appendix 2).
When comparing the EHR-DM practices and the EPS practices
using the end-of-season dataset, the EPS practices were slightly
older, the proportion of 65 years and over was 21.64%
(n=9842/45,519) in EHR-DM compared with 25.44%
(6586/25,888) in EPS (Table 1). The EHR-DM practices also
had a smaller proportion of at-risk patients at 40.43%
(18,403/45,519) compared with 45.21% (11,703/25,888) in the
EPS practices.
Figure 1. Age and sex distribution of pilot practices compared against the census.
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Table 1. Summary of practice population from end of season cohort.
Vaccination status (cohort)Variables
EPSbEHR-DMa
36Number of practices
Age group (years)
<5
535 (2.07)1097 (2.41)n (%)
1.902.27LCIc, %
2.242.55UCId, %
5-14
2638 (10.19)4725 (10.38)n (%)
9.8210.10LCI, %
10.5610.66UCI, %
15-64
16,129 (62.30)29,855 (65.59)n (%)
61.7165.15LCI, %
62.8966.03UCI, %
65+
6586 (25.44)9842 (21.62)n (%)
24.9121.64LCI, %
25.9722.00UCI, %
Gender
Male
12,853 (49.65)23,035 (50.64)n (%)
49.0450.19LCI, %
50.2651.10UCI, %
Female
13,035 (50.35)22,466 (49.36)n (%)
49.7448.90LCI, %
50.9649.81UCI, %
Risk group
Specific risk group
11,703 (45.21)18,403 (40.43)n (%)
44.6039.98LCI, %
45.8140.88UCI, %
aEHR-DM: electronic health record data mining.
bEPS: enhanced passive surveillance.
cLCI: lower confidence interval.
dUCI: upper confidence interval.
Measures
Most vaccinations took place between weeks 39 and 45 (Figure
2). From the weekly cumulative data extractions (weeks 35-49),
19.57% (15,863/81,040) of the registered practice population
overall and 57.48% (9969/17,344) of people aged 65 years or
older were vaccinated (Table 2).
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Figure 2. Cumulative vaccines.
Table 2. Summary of vaccinations from weekly data extractions by risk group.
Vaccination status (weekly cumulated data)Variables
EPSbEHR-DMa vaccinated (Non-GSK)
Vaccinated (All)Vaccinated (GSK)Vaccinated (Non-GSK)
3216Number of practices
7223 (24.85)3616 (12.44)3607 (12.41)8640 (16.62)n (%)
24.3512.0612.0316.30LCIc, %
25.3512.8212.7916.95UCId, %
Risk group
Specific risk group
6268 (47.88)3301 (25.21)2967 (22.66)7422 (36.26)n (%)
47.0224.4721.9435.60LCI, %
48.7325.9623.3836.92UCI, %
Under 4 years old
166 (15.99)53 (5.11)113 (10.89)277 (14.70)n (%)
13.783.859.0613.11LCI, %
18.216.4512.8116.30UCI, %
65 years or older
4771 (68.71)2641 (38.03)2130 (30.67)5198 (49.98)n (%)
67.6136.9029.5949.02LCI, %
69.8039.1731.7550.94UCI, %
aEHR-DM: electronic health record data mining.
bEPS: enhanced passive surveillance.
cLCI: lower confidence interval.
dUCI: upper confidence interval.
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Enhanced Passive Surveillance Practices
In the 3 practices that conducted yellow card–based surveillance,
the staff managed to hand out the cards to 61. 24% (4150/6776)
of the vaccinees, and of these cards, 1.97% (82/4150) were
returned to the GP offices, which represented 1.21% (82/6776)
of the vaccinated population covered by this surveillance system.
Some practices found it challenging to interpret and link the
free-text comments on the cards to the specified AEI codes.
With this respect, 1 practice faced some challenges to record
all the information on the returned cards into the practice EHR
system, the main reason being the difficulty to transcribe the
events reported in the yellow cards to the electronic system.
Of those vaccinated (19.57% (15,863/81,040) of the population);
77.20% (12,247/15,863) were vaccinated using a non-GSK
vaccine. The non-GSK vaccines that patients were administered
were manufactured by Astra Zeneca, Sanofi Pasteur Europe,
Seqirus Vaccines Limited, and Abbot Biologicals.
Adverse Events of Interest
From the weekly cumulative data extractions (weeks 35-49),
the rates of AEIs in the 14-days postvaccination between GSK
and non-GSK vaccines were similar: non-GSK=3.02%
(370/12,247; 95% CI 2.72-3.33) and GSK=2.63% (95/3616;
95% CI 2.13-3.15) (Table 3). The most common AEIs
presenting were respiratory, fever, and musculoskeletal
symptoms (Multimedia Appendix 3).
The GSK vaccine had fewer AEI presentations of respiratory
symptoms and fever but more musculoskeletal symptoms. The
rates of these AEIs were as follows:
• Respiratory—0.96% (95% CI 0.79%-1.14%, 118/12,247)
for non-GSK and 0.88% (95% CI 0.58%-1.19% 32/3616)
for GSK vaccine.
• Fever—0.79% (95% CI 0.64%-0.96%, 97/12,247) for
non-GSK and 0.66% (95% CI 0.41%-0.94%, 24/3616) for
GSK vaccine.
• Musculoskeletal conditions—0.51% (95% CI 0.39%-0.65%,
63/12,247) for non-GSK and 0.91% (95% CI
0.61%-1.24%,33/3616) for GSK vaccine (Multimedia
Appendix 3).
The highest rate of AEIs was identified in adults aged 15 to 64
years for GSK vaccines (3.2%; 25/781) (Table 3).
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Table 3. Summary of adverse events of interest from weekly data extractions.
Vaccination status (weekly cumulated data)Any AEIa
EPScEHR-DMb vaccinated (Non-GSK)
Vaccinated (All)Vaccinated (GSK)Vaccinated (Non-GSK)
3216Number of practices
Total
126 (1.74)95 (1.32)31 (0.43)339 (3.92)n (%)
1.451.070.293.52LCId, %
2.051.580.584.34UCIe, %
Age groups (years)
<5
2 (1.20)1 (0.60)1 (0.60)15 (5.42)n (%)
0.002.310.002.12LCI, %
5.666.157.506.06UCI, %
5-14
2 (0.36)1 (0.18)1 (0.18)24 (3.37)n (%)
0.001.320.000.98LCI, %
5.262.895.882.50UCI, %
15-64
38 (2.20)25 (3.20)12 (0.69)111 (4.53)n (%)
1.732.952.053.11LCI, %
3.934.194.484.46UCI, %
65+
84 (1.76)67 (1.40)17 (0.36)189 (3.64)n (%)
1.67%2.27%1.95%2.34%LCI, %
2.76%2.99%3.16%3.11%UCI, %
Risk group
Any risk group
116 (1.85)87 (1.39)29 (0.46)293 (3.95)n (%)
1.531.100.303.52LCI, %
2.191.690.644.39UCI, %
aAEI: adverse events of interest.
bEHR-DM: electronic health record data mining.
cEPS: enhanced passive surveillance.
dLCI: lower confidence interval.
eUCI: upper confidence interval.
Hospital Admissions
We explored hospital admission data recorded in the practice
EHR. The rate of admissions of vaccinees with an AEI was
2.50% (44/1,761; 95% CI 1.8-3.2).
Those receiving GSK vaccine had a numerically lower rate of
hospital admission, although small numbers were reported. For
example, 2% (2/92; 95% CI 2.2%-3.3%) of people vaccinated
with GSK influenza vaccine were admitted to hospital with an
AEI in the 14 days following vaccination, while in the non-GSK
vaccines group, the rate was 3.9% (13/333; 95% CI 1.8%-2.1%).
There were timeliness, completeness, and accuracy issues with
the retrieved hospital data. The hospital admission data and
diagnoses took up to 10 to 20 days to be recorded in the
practices’ EHR and, in some cases, up to 42 days.
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Analyses
End-of-Season and Weekly Comparison
The AEIs reported in the end of season and weekly extractions
were comparable. For example, focusing on GSK vaccines, for
any adverse event, the end-of-study cohort had an AEI recording
of 92/3434 (2.68%) and weekly report of 95/3616 (2.63%). For
GSK vaccines, the largest difference in AEIs was for any
sensitivity or anaphylaxis (end of season: n=0, 0%; cohort: n=1,
0.03%).
Data Extraction From the Royal College of General
Practitioners’ Research and Surveillance Centre
Overall, the study data were comparable with that of the rest of
the RCGP RSC (see Multimedia Appendix 3). This suggests
that the AEIs reporting patterns from the 9 GPs recruited and
the RCGP RSC were similar and that the data extraction
approach was valid.
Timeliness was comparable with RCGP RSC. Data were
extracted each week using the same automated system.
However, 2 practices required local extracts (carried out where
the remote systems installation failed); these 2 practices had
delays of up to 2 weeks, particularly early in the observation
period.
The RCGP RSC rate of overall influenza vaccine uptake
(excluding the study practices) is 21.80% (238,519/1,094,352);
the overall rate of these 9 practices, using the end-of-study
cohort data, was 20.73% (14,801/71,407) suggesting a good
completeness of the study data for vaccine uptake.
Discussion
Principal Findings
This study showed that using GP data for EHR-DM was a
feasible method of near real-time surveillance. This was
demonstrated by the timeliness of data extraction and the validity
of the data.
The use of yellow cards (EPS) to enhance surveillance was not
successful as there was only a 1.97% (82/4150) return rate; and
this small additional return rate did not yield useful additional
information. However, there were only 3 practices in this group.
Rates of AEI (within 14 days postvaccination) in the vaccinated
group were around 3% (3.02% 333/11,367 for non-GSK and
2.63% 92/3434 for GSK) with around 1% (150/15,863) of AEIs
were respiratory conditions. The differences in rates were not
statistically significant, and no safety concerns were raised
during the weekly assessment or at the end of the study period.
Implications of Findings
The study demonstrated the feasibility of setting up a network
that could, with further refinement, rapidly detect potential
safety concerns, allowing prompt investigation if deemed
appropriate [18], originating from a significant change in AEIs
associated with influenza vaccination using EHR-DM observing,
for example, trends from week to week.
This network still needs additional adaptations to be worked
out in the next phase of its implementation. For example, further
thought needs to be given regarding improving the return rate
of yellow cards. To improve the return rate, any future ADR
card should ideally have predefined categories that patients can
tick if present (or record if no AEI is experienced following
vaccination), to standardize coding into the EHR.
To harmonize and standardize the Enhanced Safety Surveillance
in Europe, one recommendation could be to establish a network
of organizations involved in EHR data mining in real time,
supplemented with vaccination-customized ADR cards (ie,
yellow cards in this study) reporting scheme, with criteria
defining the prerequisites of data quality. However, a yellow
card is not a good long-term choice of color or label. In the
United Kingdom, yellow cards are developed by the MHRA
and are generally completed when a GP suspects an ADR related
to the vaccination. In this study, the approach was to collect as
comprehensively as possible AEIs, prespecified by the EMA,
regardless of the possible causal association with immunization.
Another potential way to collect AEI following vaccination
could be to develop a mobile phone application to collect events
in a more comprehensive manner. This approach could be an
interesting approach to overcome the suboptimal return. Future
research could investigate the feasibility of designing such an
app to collect this information in a more reliable manner.
Generalizability
A near real-time enhanced brand-specific surveillance network
could produce weekly reports of AEIs to meet the EMA
requirements. The data extraction element of the project could
readily be extended; the yellow card scheme could be refined
and expanded. Introducing an ADR card as part of the process
may be an optimal and sustainable way to stimulate reporting
of AEIs from those with a lower propensity to consult (ie, for
mild events).
Data collection over several seasons may be required to achieve
a better understanding of background rates of AEIs. A particular
challenge is that people immunized in the first weeks of
immunization may differ from those immunized in subsequent
weeks due to annual recommendations to promptly vaccinate
the more vulnerable patients early in the season.
It is feasible to set up a weekly reporting, using an enhanced
passive and EHR-DM surveillance system, to detect
EMA-specified AEIs across specific brands; though further
refinements are needed before such a system can be fully
operationalized.
Limitations
Data were inevitably passive surveillance data, largely derived
from medically attended events for those who consult.
Considering that some groups have a lower propensity to consult
(eg, men [19]), this is a likely confounding factor. Future EPS
may need to be designed to be more inclusive of less represented
groups; for instance, using customized ADR cards to
continuously enhance the reporting.
A further limitation of our design was the potential bias in the
practice selection for EPS, which was conditional on the
willingness of practice to participate in the study and hand out,
collect, and code any data on the yellow cards. We drew
JMIR Public Health Surveill 2019 | vol. 5 | iss. 4 | e12016 | p. 9http://publichealth.jmir.org/2019/4/e12016/
(page number not for citation purposes)
de Lusignan et alJMIR PUBLIC HEALTH AND SURVEILLANCE
XSL•FO
RenderX
conclusions about the unsuitability of the yellow card on basis
of data from 3 practices, not selected at random. Return rates
were low and what was written on the cards was challenging to
transcribe and thus to code consistently.
In addition, in the United Kingdom, vaccines are preferentially
recommended for different age and risk groups which preclude
any possibility to systematically compare the findings from
different vaccine brands. In addition, the sample for future
studies could have improved representativeness by recruiting
more inner-city practices. Our study practice populations were
less ethnically mixed and less deprived than the English national
average, likely due to a lack of inner-city practices.
Our remote data extraction system was reasonably reliable,
although it had gaps. It is challenging to use a local extract
system in a timely way, although it did fill gaps in our data.
One other challenge was to properly analyze all the collected
data to allow near real-time assessment. In the longer term,
comparing rates with historic data may be an additional option
to have more insights on baseline rates as a basis for comparison
with findings in the current season. For this study, we had a
lack of historical background rates of AEI in the same
population or availability of an appropriate comparison group.
In future studies, we should either compare rates with AEIs
derived from the RCGP or from previous years of these studies,
assuming that the study design and the approach remain overall
unchanged.
A limitation of our design was training GPs in coding. While
this should help with data within the season, it has the potential
to produce biased results when comparing with historical data
when no training was given. Furthermore, the preferred code
list given to practices (Multimedia Appendix 1) notes that these
codes should be used for adverse events postvaccination. In this
respect, it does not appear to use as baseline for comparison
historical data where no specific training was provided.
Conclusions
Overall, this study showed that using GP data was a feasible
method for enhanced near-real time surveillance in terms of
EHR-DM. However, the use of yellow cards (EPS) in GP did
not capture a significant amount of additional data. There are
many lessons learnt from this initial study, and these are
reflected in the limitations of the design and study approach.
Future enhanced surveillance should focus on ways to improve
and standardize AEIs reporting, data collection, and extraction.
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